Investor Notice
Pomerantz LLP is conducting an investigation into possible securities law violations involving Praxis Precision Medicines, Inc. (NASDAQ: PRAX). Shareholders are encouraged to reach out to Danielle Peyton at [email protected] or call 646-581-9980, extension 7980.
Investigation Focus
The probe focuses on whether Praxis and its executives engaged in fraudulent or unlawful business conduct. This follows Praxis's August 4, 2025, announcement of its Q2 financial results, which included preliminary data on its anti-seizure drug vormatrigine. The company disclosed that 36 out of 61 patients experienced adverse effects, and nearly a quarter of participants withdrew from the study.
Stock Market Reaction
Subsequently, Praxis’s stock decreased by $3.00, closing at $51.09 on August 4, 2025.
About Pomerantz LLP
Founded over 85 years ago by Abraham L. Pomerantz, Pomerantz LLP is a leading firm in securities, corporate, and antitrust class action litigation, with offices worldwide. The firm has a longstanding history of representing investors in securities fraud cases and recovering substantial damages for class members.